Gene Therapy for Retinitis Pigmentosa: Current Challenges and New Progress

Area of Science:

• Ophthalmology
• Genetics
• Molecular Biology

Background:

• Retinitis pigmentosa (RP) is a leading cause of inherited blindness, affecting 1 in 5000 individuals globally.
• Characterized by photoreceptor cell loss and retinal pigment epithelium atrophy, RP stems from over 3000 mutations in approximately 90 genes.
• Effective treatments for RP have been historically challenging due to its genetic complexity.

Purpose of the Study:

• To review the latest advancements in gene editing research for treating retinitis pigmentosa (RP).
• To explore the application of gene therapy in correcting genetic defects responsible for RP.
• To discuss prevalent genes implicated in RP and current genome-editing strategies.

Main Methods:

• Review of current scientific literature on gene therapy and gene editing for RP.
• Analysis of gene editing strategies targeting prevalent RP-associated genes.
• Discussion of viral and non-viral vector applications in gene correction.

Main Results:

• Gene therapy, particularly gene editing, shows significant promise for treating RP.
• Advancements in identifying new gene loci and compounds are expanding treatment options.
• Genome-editing strategies are being developed to correct diverse disease-causing mutations in RP.

Conclusions:

• Gene editing represents a cutting-edge approach to address the genetic basis of retinitis pigmentosa.
• This technology holds the potential for restoring vision by correcting specific genetic mutations.
• Continued research in gene editing offers hope for more effective therapies for this prevalent inherited eye disease.